阿柏西普治疗性延长方案用于息肉样脉络膜血管病变的两年结果 - Suppr

Suppr

超能文献

Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy.

作者信息

Călugăru Dan, Călugăru Mihai

机构信息

Department of Ophthalmology, University of Medicine Cluj-Napoca, Cluj-Napoca, Romania.

出版信息

Graefes Arch Clin Exp Ophthalmol. 2018 Jan;256(1):221-223. doi: 10.1007/s00417-017-3784-9. Epub 2017 Aug 21.

DOI:10.1007/s00417-017-3784-9

PMID:28828522

Abstract

摘要

相似文献

Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy.阿柏西普治疗性延长方案用于息肉样脉络膜血管病变的两年结果

Graefes Arch Clin Exp Ophthalmol. 2018 Jan;256(1):221-223. doi: 10.1007/s00417-017-3784-9. Epub 2017 Aug 21.

Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy.阿柏西普治疗性延长方案用于息肉状脉络膜血管病变的两年结果

Graefes Arch Clin Exp Ophthalmol. 2017 Oct;255(10):1891-1897. doi: 10.1007/s00417-017-3718-6. Epub 2017 Jul 1.

One-year outcomes of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy.玻璃体内注射阿柏西普治疗息肉状脉络膜血管病变的“治疗-延长”方案的一年疗效

Jpn J Ophthalmol. 2017 Mar;61(2):150-158. doi: 10.1007/s10384-016-0492-7. Epub 2016 Dec 7.

Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection.

Jpn J Ophthalmol. 2017 Mar;61(2):204-205. doi: 10.1007/s10384-016-0475-8. Epub 2016 Oct 5.

CHOROIDAL THICKNESS AS A PROGNOSTIC FACTOR OF PHOTODYNAMIC THERAPY WITH AFLIBERCEPT OR RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.脉络膜厚度作为阿柏西普或雷珠单抗光动力疗法治疗息肉状脉络膜血管病变的预后因素

Retina. 2017 Oct;37(10):1866-1872. doi: 10.1097/IAE.0000000000001427.

Efficacy of aflibercept for polypoidal choroidal vasculopathy in Caucasians.阿柏西普治疗白种人息肉状脉络膜血管病变的疗效。

Acta Ophthalmol. 2018 Feb;96(1):e94-e95. doi: 10.1111/aos.13461. Epub 2017 Jun 21.

Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration.阿柏西普治疗延长方案用于厚脉络膜新生血管病变和1型新生血管性年龄相关性黄斑变性的疗效

Jpn J Ophthalmol. 2018 Mar;62(2):144-150. doi: 10.1007/s10384-018-0562-0. Epub 2018 Feb 6.

ANGIOGRAPHIC FINDINGS OF RANIBIZUMAB-RESISTANT POLYPOIDAL CHOROIDAL VASCULOPATHY AFTER SWITCHING TO A TREAT-AND-EXTEND REGIMEN WITH INTRAVITREAL AFLIBERCEPT.玻璃体内注射阿柏西普转换为治疗并延长方案后，对雷珠单抗耐药的息肉状脉络膜血管病变的血管造影结果

Retina. 2016 Nov;36(11):2158-2165. doi: 10.1097/IAE.0000000000001047.

Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection.转换为玻璃体内注射阿柏西普后息肉状脉络膜血管病变患者的黄斑中心凹下脉络膜厚度

Jpn J Ophthalmol. 2016 Jan;60(1):35-41. doi: 10.1007/s10384-015-0411-3. Epub 2015 Sep 9.

Comment on: Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience.评论：阿柏西普治疗印度患者复发性或顽固性息肉样脉络膜血管病变的早期经验。

Indian J Ophthalmol. 2018 Feb;66(2):348-349. doi: 10.4103/ijo.IJO_1034_17.

引用本文的文献

Romanian ophthalmologists in the renowned ophthalmic journals worldwide.罗马尼亚眼科医生发表于全球知名眼科期刊上的文章。（原英文表述不太完整准确，推测完整意思应该是类似这样，若按照字面翻译是：罗马尼亚眼科医生在全球著名眼科期刊里）

Rom J Ophthalmol. 2018 Oct-Dec;62(4):260-269.

本文引用的文献

Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy.阿柏西普治疗性延长方案用于息肉状脉络膜血管病变的两年结果

Graefes Arch Clin Exp Ophthalmol. 2017 Oct;255(10):1891-1897. doi: 10.1007/s00417-017-3718-6. Epub 2017 Jul 1.

Six-year outcomes of antivascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy.抗血管内皮生长因子单药治疗息肉状脉络膜血管病变的六年随访结果

Br J Ophthalmol. 2018 Jan;102(1):97-101. doi: 10.1136/bjophthalmol-2017-310448. Epub 2017 May 25.

Long-term Outcomes of Aflibercept Treatment for Neovascular Age-related Macular Degeneration in a Clinical Setting.阿柏西普治疗临床环境中新血管性年龄相关性黄斑变性的长期疗效

Am J Ophthalmol. 2017 Feb;174:185-186. doi: 10.1016/j.ajo.2016.11.022. Epub 2016 Dec 23.

Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration.雷珠单抗与阿柏西普治疗年龄相关性黄斑变性的再治疗时间和视觉功能比较

Am J Ophthalmol. 2017 Feb;174:181-182. doi: 10.1016/j.ajo.2016.11.005. Epub 2016 Dec 5.

Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration.阿柏西普按需治疗方案用于持续性新生血管性年龄相关性黄斑变性的长期疗效

Am J Ophthalmol. 2017 Jan;173:145-146. doi: 10.1016/j.ajo.2016.07.029. Epub 2016 Nov 11.

Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy.玻璃体腔注射阿柏西普的短期疗效取决于息肉样脉络膜血管病变的血管造影分类。

Br J Ophthalmol. 2017 Jun;101(6):758-763. doi: 10.1136/bjophthalmol-2016-309144. Epub 2016 Sep 5.

Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid.年龄相关性黄斑变性患者早期持续性视网膜液对抗 VEGF 方案的反应差异。

Ophthalmology. 2016 Sep;123(9):1856-64. doi: 10.1016/j.ophtha.2016.05.016. Epub 2016 Jun 28.

Choroidal Thickness Changes After Intravitreal Antivascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration: Ranibizumab Versus Aflibercept.玻璃体内注射抗血管内皮生长因子疗法治疗年龄相关性黄斑变性后脉络膜厚度的变化：雷珠单抗与阿柏西普对比

J Ocul Pharmacol Ther. 2015 Jul-Aug;31(6):357-62. doi: 10.1089/jop.2014.0160. Epub 2015 Jun 3.

Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes.玻璃体内注射雷珠单抗和阿柏西普对猴眼视网膜和脉络膜组织的不同影响。

Br J Ophthalmol. 2014 Jun;98(6):813-25. doi: 10.1136/bjophthalmol-2013-304019. Epub 2014 Jan 23.

Indocyanine green angiographic and optical coherence tomographic findings support classification of polypoidal choroidal vasculopathy into two types.吲哚菁绿血管造影和光相干断层扫描结果支持将息肉样脉络膜血管病变分为两型。

Acta Ophthalmol. 2013 Sep;91(6):e474-81. doi: 10.1111/aos.12110. Epub 2013 Jul 15.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验